Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ¹Ì±¹ÀÇ ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼®
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

¹Ì±¹ÀÇ ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Analysis of the United States Glaucoma Pharmaceuticals Market

¸®¼­Ä¡»ç Frost & Sullivan
¹ßÇàÀÏ 2012³â 01¿ù »óǰÄÚµå 230000
ÆäÀÌÁö Á¤º¸ 119 Pages
°¡°Ý
US $ 6,000 £Ü 7,149,000 Web Access (Regional License)
US $ 6,500 £Ü 7,744,700 Web Access (Regional License) & Hard Copy


Frost & Sullivan ¿¡¼­ 2012³â 01¿ù ¿¡ ¹ßÇàÇÑ ¡¸¹Ì±¹ÀÇ ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¡¹ º¸°í¼­´Â 119 Pages·Î ±¸¼ºµÇ¾î, US $6,000 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ 2008-2016³â ³ì³»Àå(Glaucoma) Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇϰí, Ãâ½Ã Á¦Ç°, °³¹ß ´Ü°è¿¡ ÀÖ´Â Á¦Ç° ºÐ¼®, ȯÀÚ¼ö ¹× ¸ÅÃâ ¿¹Ãø, ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ ºÐ¼®, ºÎ¹®º° ½ÃÀå ºÐ¼® Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

1. ¸ñÂ÷

  • °³¿ä
  • ½ÃÀå °³¿ä
  • ³ì³»Àå Ä¡·áÁ¦ ½ÃÀå
    • ¿ÜºÎ °úÁ¦ : ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ
    • ¿¹Ãø ¹× µ¿Çâ
    • ¼ö¿ä ºÐ¼®
    • ½ÃÀå Á¡À¯À² ¹× °æÀï ºÐ¼®
  • ÇÁ·Î½ºÅ¸±Û¶õµò(Prostaglandin) ºÎ¹® ºÐ¼®
  • ¥âÂ÷´ÜÁ¦(Beta-Blocker) ºÎ¹® ºÐ¼®
  • ¥á-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦(Alpha-Adrenergic Agonist) ºÎ¹® ºÐ¼®
  • ź»êÅ»¼ö¼ÒÈ¿¼Ò ÀúÇØÁ¦(CAI : Carbonic Anhydrase Inhibitor) ºÎ¹® ºÐ¼®
  • ´ÙÁ¦È¥ÇÕÁ¦(FDC) ºÎ¹® ºÐ¼®
  • °á·Ð
  • ºÎ·Ï
LSH
Back to Top